Emerson and GE Healthcare collaborate on biopharma manufacturing
20 November, 2015GE Healthcare's Life Sciences business and Emerson Process Management have announced a collaboration aimed at increasing productivity and improving efficiency in the production of biopharmaceuticals such as monoclonal antibodies and vaccines.
Invion aims for Phase 3 smoking cessation trial
17 November, 2015Invion claims that the results from its Phase 2 clinical trial of INV102 (nadolol) in patients trying to quit smoking warrant progression to a Phase 3 trial.
Two drug discovery initiatives for UniQuest
11 November, 2015The commercialisation company of The University of Queensland, UniQuest, will be part of two separate drug discovery initiatives.
Invion's share purchase plan and asthma trial
10 November, 2015Invion has opened a share purchase plan (SPP), allowing eligible shareholders to purchase up to $15,000 worth of shares at a discount and without any brokerage or transaction costs.
A heart failure drug that reduces scar tissue
09 November, 2015Drug development company Armaron Bio has begun its Phase II clinical trial for NP202, its lead candidate drug for heart failure.
The importance of transparency
03 November, 2015 by Dr Andrew Weekes, Medical Director, GSK AustraliaStudying experimental medicines in people is a vital part of the development process for all new medicines and vaccines. GSK Australia Medical Director Dr Andrew Weekes recognises the importance of publicly disclosing this research.
Potential new treatment for tuberculosis
29 October, 2015Scientists have discovered a potential new treatment for tuberculosis — a disease whose resistance to current medical therapies has enabled it to infect 30% of the globe's population.
Tennis elbow tendon treatment results
28 October, 2015Orthocell has released positive follow-up data from a study of its tendon cell treatment for tennis elbow in workers compensation patients.
Licence agreement for TGR immunoassay technology
26 October, 2015TGR BioSciences has announced a European licence agreement with Prime Diagnostics — a developer of high-quality diagnostics, technologies and services for the agricultural sector.
Nanodelivery trials get the go-ahead
22 October, 2015Medlab Clinical has been granted ethics approval to begin two separate human trials using its nanotechnology delivery platform, NanoCelle. The platform, previously developed for cannabis research, converts pharmaceuticals into nanoparticle form.
Cynata collaborates on cell therapy for cancer
14 October, 2015Cynata Therapeutics will collaborate with Massachusetts General Hospital on the development of modified mesenchymal stem cells (MSCs) to treat cancer.
Phosphagenics restructure effective immediately
13 October, 2015Drug delivery company Phosphagenics has announced a corporate restructure, effective immediately, following its recent strategic review.
ResMed completes Curative Medical acquisition
12 October, 2015ResMed has completed its acquisition of Curative Medical, a provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories to the Chinese market.
Paranta Biosciences commences cystic fibrosis trial
06 October, 2015Paranta Biosciences has successfully closed a $7 million financing round, which it will use to fund the development of treatments for inflammatory and fibrotic lung diseases.
A new drug analysis method
02 October, 2015An international team of scientists has been working with a major biopharmaceutical company to investigate new ways to characterise protein formulations.
